Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disease that affects frontal and temporal regions of the brain. Two proteins indicated in the pathology are tau and the recently discovered TDP-43. Major manifestations include progressive aphasia and a disorder of social comportment. The diagnosis of a patient includes a detailed cognitive exam, clinical testing, and neuroimaging techniques. The current goal of therapy for FTLD is symptomatic management with medications borrowed from other conditions. Nonpharmacologic management such as behavioral interventions and environmental engineering are also efficacious in optimizing quality of life.
Grossman M.Frontotemporal dementia: a review. J Int Neuropsychol Soc . 2002;8:564-583.
2.
Ratnavalli E. , Brayne C., Dawson K., Hodges JRThe prevalence of frontotemporal dementia . Neurology. 2002 ;58: 1615-1621.
3.
Lee VMY , Goedert M., Trojanowski JQNeurodegenerative tauopathies. Ann Rev Neurosci. 2001;24:1121-1159.
4.
Mackenzie IR , Baker M., Pickering-Brown S., et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain. Nov 2006;129(Pt 11):3081-3090.
5.
Neumann M., Sampathu DM, Kwong LK, et al. Ubiquinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclereosis. Science. 2006 ;314: 130-133.
6.
Stevens M., van Duijn CM, Kamphorst W., et al. Familial aggregation in frontotemporal dementia. Neurology. 1998; 50:1541-1545.
7.
Goldman J., Farmer J., Van Deerlin VM, et al. Frontotemporal dementia: genetics and genetic counseling dilemmas . Neurologist. 2004;10:227-234.
8.
Rosso SM, van Swieten JCNew developments in frontotemporal dementia and parkinsonism linked to chromosome 17. Curr Opin Neurol. 2002;15:423-428.
9.
Hutton M., Lendon CL, Rizzu P., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702-705.
10.
Clark LN, Poorkaj P., Wszolek Z., et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA. 1998; 95:13103-13107.
11.
Morris HR, Khan MN, Janssen JC, et al. The genetic and pathological classification of familial frontotemporal dementia. Arch Neurol. 2001;58:1813-1816.
12.
Rizzu P., Van Swieten JC, Joosse M.High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet. 1999;64:414-421.
13.
Houlden H., Baker M., Adamson J., et al. Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia. Ann Neurol. 1999;46:243-248.
14.
Poorkaj P., Grossman M., Steinbart E., et al. Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer's dementia. Arch Neurol. 2001;58:383-387.
15.
Baker M., Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006; 442:916-919.
16.
Gass J., Cannon A., Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006; 15:2988-3001.
17.
Grossman M. , Lee C., Morris J., Stern MB, Hurtig HIAssessing resource demands during sentence processing in Parkinson's disease. Brain Lang. 2002;80:603-616.
18.
Snowden JS, Neary D., Mann DMFronto-temporal Lobar Degeneration: Fronto-temporal Dementia, Progressive Aphasia, Semantic Dementia. New York: Churchill Livingstone; 1996.
19.
Neary D., Snowden JS, Gustafson L., et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
20.
Forman MS, Farmer J., Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59:952-962.
21.
Knopman DS, Boeve BF, Parisi JE, et al. Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol. 2004;57:480-488.
22.
Hodges JR, Davies RR, Xuereb J., et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol. 2004; 56:399-406.
23.
Bian H., Grossman.Frontotemporal lobar degeneration: recent progress in antemortem diagnosis. Acta Neuropathol. 2007. In press.
24.
Farmer J., Grossman M.Frontotemporal dementia: an overview. Alzheimers Care Q. 2005;6:225-232.
25.
Johnson JK, Head E., Kim R., Starr A., Cotman CWClinical and pathological evidence for a frontal variant of Alzheimer disease . Arch Neurol. 1999;56:1233-1239.
26.
Rascovsky K. , Salmon DP, Ho GJ, et al. Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD. Neurology. 2002;58:1801-1808.
27.
Grossman M., Libon DJ, Forman MS, et al. Distinct antemortem profiles in pathologically defined patients with frontotemporal dementia. Arch Neurol. 2007. In press.
28.
Folstein MF , Folstein SF, McHugh PR "Mini Mental State." A practical method for grading the cognitive state of patients for the clinician . J Psychiatr Res. 1975;12: 189-198.
29.
Gregory CA, Hodges JRFrontotemporal dementia: use of consensus criteria and prevalence of psychiatric features. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9:145-153.
30.
Miller BL, Cummings JL, Villanueva-Meyer J.Frontal lobe degeneration: clinical, neuropsychological, and SPECT characteristics . Neurology. 1991;41:1374-1382.
31.
Dubois B., Slachevsky A., Litvan I., Pillon B.The FAB: a frontal assessment battery at bedside. Neurology . 2000; 55:1621-1626.
32.
Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz WP, Hodges JRA brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia . Neurology . 2000;55:1613-1620.
Eslinger PJ , Moore P., Troiani V., et al. Oops! Resolving social dilemmas in frontotemporal dementia. Neurol, Neurosurg and Psychiatry . 2007. In press.
35.
Gorno-Tempini ML, Ogar JM, Brambati SM, et al. Anatomical correlates of early mutism in progressive non-fluent aphasia. Neurology . 2006;67:1849-1851.
36.
Mummery CJ, Patterson K., Price CJ, Hodges JRA voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol . 2000;47:36-45.
37.
McNeill R., Sare GM, Manoharan M., et al. Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007;78:350-355.
38.
Diehl-Schmid J., Grimmer T., Drzezga A., et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study . Neurobiol Aging. 2007;28:42-50.
39.
Avants B., Grossman M., Gee JCFrontotemporal dementia induced annualized gray matter loss using diffeomorphic morphometry. Alzheimer Dis Associated Disord . 2004;19: S25-S28.
40.
Grossman M. , Farmer J., Leight S., et al. Cerebrospinal fluid profile distinguishes frontotemporal dementia from Alzheimer's disease . Ann Neurol . 2005;57:721-729.
41.
Blier P., Ward NMIs there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53: 193-203.
42.
Moretti R., Torre P., Antonello RM, Cazzato G., Bava A.Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms . Eur Neurol. 2003;49: 13-19.
43.
Deakin JB, Rahman S., Nestor PJ, Hodges JR, Sahakian BJParoxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology . 2004; 172:400-408.
44.
Lebert F., Stekke W., Hasenbroekx C., Pasquier F.Frontotemporal dementia: a randomised, controlled trial with trazodone . Dement Geriatr Cogn Disord. 2004;17: 355-359.
45.
Schneider LS , Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525-1538.
46.
Caballero J. , Hitchcock M., Scharre D., Beversdorf D., Nahata MCCognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Clin Ther. 2006;28:1695-1700.
47.
Herrmann N.Valproic acid treatment of agitation in dementia . Can J Psychiatry. 1998;43:69-72.
48.
Doody RS, Stevens JC, Beck C., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56: 1154-1166.
49.
Mendez MF, Shapira JS, McMurtray A., Licht E.Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84-87.
50.
Moretti R., Torre P., Antonello RM, Cattaruzza T., Cazzato G., Bava A.Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931-937.
51.
Light SA, Holroyd S.The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia. J Psychiatry Neurosci . 2006;31:132-134.
52.
Galynker I. , Ieronimo C., Miner C., Rosenblum J., Vilkas N., Rosenthal R.Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci . 1997;9:231-239.
53.
Livingston G., Johnston K., Katona C., Paton J., Lyketsos CG, Old Age Task Force of the World Federation of Biological Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry . 2005;162:1996-2021.
54.
Soliveri P., Piacentini S., Girotti F.Limb apraxia in corticobasal degeneration and progressive supranuclear palsy . Neurology. 2005;64:448-453.
55.
Finucane TE , Christmas C., Travis K.Tube feeding in patients with advanced dementia: a review of the evidence. JAMA. 1999;282:1365-1370.
56.
Garcia AD, Thomas DRAssessment and management of chronic pressure ulcers in the elderly . Med Clin North Am. 2006;90:925-944.
